Balcar, Lorenz
Semmler, Georg
Scheiner, Bernhard
Stättermayer, Albert Friedrich
Ćosić, Stefan
Schwabl, Philipp
Kazem, Niema
Mandorfer, Mattias
Hülsmann, Martin
Zuckermann, Andreas
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 29 March 2023
Accepted: 23 May 2023
First Online: 28 June 2023
Declarations
:
: L. Balcar, G. Semmler, A.F. Stättermayer, S. Ćosić, P. Schwabl and N. Kazem declare that they have no competing interests. B. Scheiner received travel support from AbbVie, Ipsen, and Gilead. M. Mandorfer served as a speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. M. Hülsmann received grant support, speaker fee and consultant honoraria from Roche Diagnostics, Bayer, Boehringer Ingelheim, Astra Zeneca, Novartis, Biopeutics, Thermo Fisher. A. Zuckermann serves on the speakers’ bureau of Paragonix, Mallincrodt, and Franz Köhler Chemie. He served on the speakers’ bureau of Sanofi-Genzyme and on the advisory board for Chiesi. T. Reiberger received grant support from AbbVie, Boehringer-Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens, and W. L. Gore & Associates; speaking honoraria from AbbVie, Gilead, Gore, Intercept, Roche, and MSD; consulting/advisory board fees from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, and Siemens; and travel support from AbbVie, Boehringer-Ingelheim, Gilead, and Roche.
: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee (EK1512/2021) and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.